Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Topamax Glaucoma Warning, Lennox-Gastaut Indication Added To Label

Executive Summary

Johnson & Johnson's Topamax (topiramate) acute myopia and secondary angle glaucoma label warnings will be the subject of a "Dear Healthcare Professional" letter.

You may also be interested in...



Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says

Centocor's efforts to increase tuberculosis screening prior to Remicade therapy are working as intended, Johnson & Johnson VP-Investor Relations Helen Short told an Oct. 16 earnings call.

Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says

Centocor's efforts to increase tuberculosis screening prior to Remicade therapy are working as intended, Johnson & Johnson VP-Investor Relations Helen Short told an Oct. 16 earnings call.

J&J Topamax Expansion Will Include Lennox-Gastaut; "Approvable" At FDA

Johnson & Johnson's first step in expanding the Topamax label within the seizure market could be for a Lennox-Gastaut syndrome indication, Group Chairman Joseph Scodari suggested during an analyst R&D day in La Jolla, Calif. May 30.

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel